Plasmodium antigens

Plasmodium antigens represent a broad and diverse category of proteins and molecules expressed by parasites of the genus Plasmodium, the causative agents of malaria. These antigens are expressed at various stages of the parasite's complex life cycle, including the pre-erythrocytic (sporozoite and liver), erythrocytic (blood), and sexual (gametocyte) stages (Nature Reviews Microbiology, 2021). They play essential roles in the parasite's survival, facilitating host cell recognition, attachment, and invasion, while also enabling the parasite to evade the host immune system through mechanisms such as antigenic variation (Frontiers in Immunology, 2020). In therapeutic development, these antigens are the primary targets for malaria vaccines and monoclonal antibodies. For example, the circumsporozoite protein (CSP) is the target of the WHO-approved RTS,S/AS01 and R21/Matrix-M vaccines, which aim to prevent the parasite from infecting the liver (World Health Organization, 2023). Other antigens, such as apical membrane antigen 1 (AMA1) and merozoite surface protein 1 (MSP1), are being investigated as targets for blood-stage vaccines to reduce clinical disease severity (The Lancet, 2021). Because this term encompasses hundreds of distinct proteins across multiple species, it is generally considered a target class rather than a single molecular target.

Other names

Malaria antigensPlasmodium falciparum antigensPlasmodium vivax antigensMalarial proteins

Induction of humoral and cellular immune responses to neutralize parasites and prevent host cell invasion (e.g., hepatocyte or erythrocyte entry).